Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos Sells 4,647 Shares

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of Cibus stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $5.30, for a total value of $24,629.10. Following the transaction, the chief financial officer now owns 74,197 shares of the company’s stock, valued at $393,244.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cibus Stock Performance

Shares of NASDAQ CBUS traded down $0.36 during midday trading on Wednesday, hitting $4.95. The stock had a trading volume of 106,565 shares, compared to its average volume of 137,380. The stock has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $8.68. Cibus, Inc. has a 1 year low of $2.86 and a 1 year high of $23.18.

Hedge Funds Weigh In On Cibus

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC boosted its holdings in shares of Cibus by 16.9% during the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock worth $12,757,000 after purchasing an additional 566,328 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Cibus by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock worth $161,000 after acquiring an additional 6,276 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Cibus during the 3rd quarter worth $33,000. Armistice Capital LLC acquired a new position in shares of Cibus during the 2nd quarter valued at about $5,083,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Cibus in the second quarter valued at about $214,000. 33.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CBUS has been the subject of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Cibus in a report on Tuesday, October 22nd. Alliance Global Partners decreased their price objective on shares of Cibus from $25.00 to $23.50 and set a “buy” rating for the company in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Cibus in a research report on Monday. Finally, Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a research report on Friday, July 19th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.